Genetron Holdings Ltd. - Company Profile

BioCentury | Jan 7, 2021

Deals

Jan. 6 Quick Takes: Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

...tests. BC Staff Ribometrix Genentech Pfizer Dewpoint Therapeutics Kite Pharma Gilead Oxford BioTherapeutics Illumina Fate Therapeutics Y-Biologics 3D Medicines Corp. Genetron Health Sino...

BioCentury | Dec 2, 2020

Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

...if that sale would cause or worsen a drug shortage. TARGETSCGRP – Calcitonin gene-related peptide BC Staff Genetron Health PegBio Minerva...

BioCentury | Oct 8, 2020

Product Development

Mapping opportunities for China’s early cancer detection boom

...the meantime, the government is helping companies build an evidence base for their tests. For example, Genetron Holdings Ltd....
...new test can slot into an established continuum of care. Karen Tkach Tuzman SeekIn Inc. Burning Rock Biotech Ltd. Genetron Health...

BioCentury | Oct 2, 2020

Regulation

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

...shares at $15, the midpoint of its proposed $14-16 range. BC Staff Veklury, remdesivir (GS-5734) SGT-001 Mesoblast Ltd. Gilead Sciences Inc. Solid Biosciences Covis Beckman Coulter Genetron Health ILiAD...

BioCentury | Aug 15, 2020

Finance

As CBMG moves to complete go-private deal, pressure on U.S.-listed Chinese companies mounts in Washington

...to list on NASDAQ in two years. Molecular diagnostics companies Burning Rock Biotech Ltd. (NASDAQ:BNR) and Genetron Holdings Ltd....

BioCentury | Jun 20, 2020

Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

...MPM Capital and OrbiMed Advisors (see “First Broad Deal With BMS” ). Also pricing were Genetron Holdings Ltd....
...Rad3 related (ATR) PPAR - Peroxisome proliferation activated receptor Paul Bonanos, Associate Editor Forma Therapeutics Inc. Repare Therapeutics Inc. Genetron Holdings Ltd. Progenity...

BioCentury | Jun 17, 2020

Finance

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

...queue moved closer to their debuts: Repare Therapeutics Inc., Forma Therapeutics Inc., Progenity Inc. and Genetron Holdings Ltd....
...a postmoney valuation of $677.5 million. Elizabeth S. Eaton, Staff Writer Royalty Pharma plc Repare Therapeutics Inc. Forma Therapeutics Inc. Genetron Holdings Ltd. Progenity...

BioCentury | Jun 9, 2020

Finance

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

...is developing gene therapies for hearing loss; radiopharmaceuticals company Fusion Pharmaceuticals Inc.; and diagnostics companies Genetron Holdings Ltd....
...Inc. Avidity Biosciences LLC Burning Rock Biotech Royalty Pharma Legend Biotechnology Corp. Arya Sciences Acquisition Corp. Lantern Pharma Inc. Akouos Inc. Fusion Pharmaceuticals Inc. Genetron Holdings Ltd. PolyPid...

BioCentury | Jun 6, 2020

Finance

Legend’s $424M NASDAQ offering pads 2020’s lead over prior years

...“IPO Queue Grows to 20 Life Sciences Companies” ). Akouos Inc., Fusion Pharmaceuticals Inc. and Genetron Holdings Ltd....

BioCentury | Apr 14, 2020

Management Tracks

Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more

...general manager of Celgene Corp.’s East Asia, Australia and New Zealand businesses. Cancer genomics company Genetron Holdings Ltd....

Items per page:

1 - 10 of 13

BioCentury | Jan 7, 2021

Deals

Jan. 6 Quick Takes: Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

...tests. BC Staff Ribometrix Genentech Pfizer Dewpoint Therapeutics Kite Pharma Gilead Oxford BioTherapeutics Illumina Fate Therapeutics Y-Biologics 3D Medicines Corp. Genetron Health Sino...

BioCentury | Dec 2, 2020

Regulation

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

...if that sale would cause or worsen a drug shortage. TARGETSCGRP – Calcitonin gene-related peptide BC Staff Genetron Health PegBio Minerva...

BioCentury | Oct 8, 2020

Product Development

Mapping opportunities for China’s early cancer detection boom

BioCentury | Oct 2, 2020

Regulation

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

BioCentury | Aug 15, 2020

Finance

As CBMG moves to complete go-private deal, pressure on U.S.-listed Chinese companies mounts in Washington

...to list on NASDAQ in two years. Molecular diagnostics companies Burning Rock Biotech Ltd. (NASDAQ:BNR) and Genetron Holdings Ltd....

BioCentury | Jun 20, 2020

Finance

Management Tracks

Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more

...general manager of Celgene Corp.’s East Asia, Australia and New Zealand businesses. Cancer genomics company Genetron Holdings Ltd....

Items per page:

1 - 10 of 13

Jan. 6 Quick Takes: Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

Mapping opportunities for China’s early cancer detection boom

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

As CBMG moves to complete go-private deal, pressure on U.S.-listed Chinese companies mounts in Washington

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

Legend’s $424M NASDAQ offering pads 2020’s lead over prior years

Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more

Jan. 6 Quick Takes: Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more

Dec. 1 Quick Takes: broader label for Blueprint; plus Minerva, Biohaven-Sosei, Genetron, PegBio, drug imports

Mapping opportunities for China’s early cancer detection boom

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

As CBMG moves to complete go-private deal, pressure on U.S.-listed Chinese companies mounts in Washington

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

Next up on NASDAQ: trio of preclinical companies ready for debuts, plus new filings

Legend’s $424M NASDAQ offering pads 2020’s lead over prior years

Kelly joins CytoDyn as CMO amid COVID-19 trials; plus Antengene, Genetron, Bolt, BioSpecifics, CMAB and more

Products & Solutions

About Biocentury

Contact

Privacy & Legal